Synlogic's stock sinks 9.3% premarket after development of hyperammonemia treatment discontinued Aug. 20, 2019 at 6:31 a.m. ET by Tomi Kilgore Synlogic started at outperform with $18 stock price target at Oppenheimer Jun. 29, 2018 at 8:51 a.m. ET by Tomi Kilgore Other News Press...
Over the last 90 days Synlogic has generated negative risk-adjusted returns adding no value to investors with long positions.In spite of fairly strong fundamental drivers, Synlogic is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for ...